

Richard A Feelders

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8291393/publications.pdf>

Version: 2024-02-01

139
papers

9,838
citations

50276

46
h-index

37204

96
g-index

143
all docs

143
docs citations

143
times ranked

8417
citing authors

#	ARTICLE	IF	CITATIONS
1	Sexual Dimorphism in Small-intestinal Neuroendocrine Tumors: Lower Prevalence of Mesenteric Disease in Premenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1969-e1975.	3.6	11
2	Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2882-e2895.	3.6	31
3	Aberrant tryptophan metabolism in stromal cells is associated with mesenteric fibrosis in small intestinal neuroendocrine tumors. <i>Endocrine Connections</i> , 2022, 11, .	1.9	2
4	Induction therapy with ¹⁷⁷ Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3203-3214.	6.4	8
5	Health-Related Quality of Life in Adrenocortical Carcinoma: Development of the Disease-Specific Questionnaire ACC-QOL and Results from the PROFILES Registry. <i>Cancers</i> , 2022, 14, 1366.	3.7	0
6	Prognostic significance of hyperammonemia in neuroendocrine neoplasm patients with liver metastases. <i>Endocrine-Related Cancer</i> , 2022, 29, 241-250.	3.1	3
7	Outcomes after Surgical Treatment of Metastatic Disease in the Adrenal Gland; Valuable for the Patient?. <i>Cancers</i> , 2022, 14, 156.	3.7	6
8	Influence of Receptor Polymorphisms on the Response to α -Adrenergic Receptor Blockers in Pheochromocytoma Patients. <i>Biomedicines</i> , 2022, 10, 896.	3.2	1
9	Prognostic value of dysnatremia for survival in neuroendocrine neoplasm patients. <i>European Journal of Endocrinology</i> , 2022, , .	3.7	1
10	Unmet needs in Cushing's syndrome: the patients' perspective. <i>Endocrine Connections</i> , 2022, 11, .	1.9	6
11	Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study. <i>European Journal of Endocrinology</i> , 2022, , .	3.7	4
12	Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. <i>Clinical Pharmacokinetics</i> , 2021, 60, 89-102.	3.5	6
13	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. <i>Pituitary</i> , 2021, 24, 104-115.	2.9	20
14	Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours. <i>Cancers</i> , 2021, 13, 443.	3.7	12
15	Levoketoconazole, the 2S,4R Enantiomer of Ketoconazole, a New Steroidogenesis Inhibitor for Cushing's Syndrome Treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1618-1630.	3.6	14
16	ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2021, 184, R51-R59.	3.7	11
17	Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 595894.	3.5	15
18	Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing's Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4). <i>Journal of the Endocrine Society</i> , 2021, 5, A516-A517.	0.2	6

#	ARTICLE	IF	CITATIONS
19	Peptide Receptor Radionuclide Therapy With ¹⁷⁷ Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3665-e3672.	3.6	23
20	Medical treatment of neuroendocrine neoplasms. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 139-144.	1.4	0
21	Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 662865.	3.5	29
22	Predicting symptomatic mesenteric mass in small intestinal neuroendocrine tumors using radiomics. <i>Endocrine-Related Cancer</i> , 2021, 28, 529-539.	3.1	4
23	The PRolaCT studies "A study protocol for a combined randomised clinical trial and observational cohort study design in prolactinoma. <i>Trials</i> , 2021, 22, 653.	1.6	7
24	Circulating adrenomedullin and B-type natriuretic peptide do not predict blood pressure fluctuations during pheochromocytoma resection: a cross-sectional study. <i>European Journal of Endocrinology</i> , 2021, 185, 507-514.	3.7	1
25	Determinants of Surgical Remission in Prolactinomas: A Systematic Review and Meta-Analysis. <i>World Neurosurgery</i> , 2021, 154, e349-e369.	1.3	12
26	Cortisol and Phosphate Homeostasis: Cushing's Syndrome Is Associated With Reversible Hypophosphatemia. <i>Frontiers in Endocrinology</i> , 2021, 12, 733793.	3.5	4
27	CYP11B1 variants influence skeletal maturation via alternative splicing. <i>Communications Biology</i> , 2021, 4, 1274.	4.4	3
28	The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 407-417.	3.6	13
29	Effect of the Tryptophan Hydroxylase Inhibitor Telotristat on Growth and Serotonin Secretion in 2D and 3D Cultured Pancreatic Neuroendocrine Tumor Cells. <i>Neuroendocrinology</i> , 2020, 110, 351-363.	2.5	14
30	Efficacy of β -Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 2381-2391.	3.6	85
31	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 773-781.	11.4	129
32	Inferior outcome of neuroendocrine tumor patients negative on somatostatin receptor imaging. <i>Endocrine-Related Cancer</i> , 2020, 27, 615-624.	3.1	15
33	β -arrestin expression in corticotroph tumor cells is modulated by glucocorticoids. <i>Journal of Endocrinology</i> , 2020, 245, 101-113.	2.6	3
34	Advances in the medical treatment of Cushing's syndrome. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 300-312.	11.4	95
35	The Effect of Perioperative Music on the Stress Response to Surgery: A Meta-analysis. <i>Journal of Surgical Research</i> , 2019, 244, 444-455.	1.6	36
36	Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3437-3449.	3.6	33

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 855-865.	11.4	60
38	Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells. <i>Hormones and Cancer</i> , 2019, 10, 107-119.	4.9	10
39	Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1336-1344.	3.6	95
40	IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. <i>Endocrine</i> , 2019, 64, 673-684.	2.3	23
41	Hyponatraemia and hyperpigmentation in primary adrenal insufficiency. <i>BMJ Case Reports</i> , 2019, 12, e227200.	0.5	8
42	Hair Glucocorticoids as a Biomarker for Endogenous Cushing's Syndrome: Validation in Two Independent Cohorts. <i>Neuroendocrinology</i> , 2019, 109, 171-178.	2.5	27
43	Total and high-affinity corticosteroid-binding globulin depletion in septic shock is associated with mortality. <i>Clinical Endocrinology</i> , 2019, 90, 232-240.	2.4	10
44	Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. <i>Drugs</i> , 2019, 79, 21-42.	10.9	54
45	Nonmosaic somatic <i>HIF2A</i> mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome. <i>Cancer</i> , 2019, 125, 1258-1266.	4.1	11
46	The role of mTOR pathway as target for treatment in adrenocortical cancer. <i>Endocrine Connections</i> , 2019, 8, R144-R156.	1.9	12
47	Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. <i>European Journal of Endocrinology</i> , 2019, 181, 45-53.	3.7	63
48	Morbidity and mortality of bone metastases in advanced adrenocortical carcinoma: a multicenter retrospective study. <i>European Journal of Endocrinology</i> , 2019, 180, 311-320.	3.7	16
49	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. <i>European Journal of Endocrinology</i> , 2019, 181, 461-472.	3.7	53
50	Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. <i>Endocrine-Related Cancer</i> , 2019, 26, R157-R179.	3.1	34
51	Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, 585-599.	3.1	16
52	Unenhanced CT imaging is highly sensitive to exclude pheochromocytoma: a multicenter study. <i>European Journal of Endocrinology</i> , 2018, 178, 431-437.	3.7	44
53	Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the ERCUSYN. <i>Clinical Endocrinology</i> , 2018, 88, 787-798.	2.4	40
54	Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. <i>European Journal of Endocrinology</i> , 2018, 178, 399-409.	3.7	37

#	ARTICLE	IF	CITATIONS
55	Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2018, 25, 245-254.	3.1	35
56	Small intestinal neuroendocrine tumours and fibrosis: an entangled conundrum. <i>Endocrine-Related Cancer</i> , 2018, 25, R115-R130.	3.1	41
57	Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 46-55.	3.6	19
58	Increased Urinary Extracellular Vesicle Sodium Transporters in Cushing's Syndrome with Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2583-2591.	3.6	15
59	Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. <i>Oncotarget</i> , 2018, 9, 14791-14802.	1.8	50
60	Coagulation Profile in Patients with Different Etiologies for Cushing Syndrome: A Prospective Observational Study. <i>Hormone and Metabolic Research</i> , 2017, 49, 365-371.	1.5	10
61	Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4617-4624.	7.0	399
62	Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. <i>Endocrine-Related Cancer</i> , 2017, 24, R261-R274.	3.1	43
63	In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2009-2018.	3.6	54
64	Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. <i>Clinical Endocrinology</i> , 2017, 87, 165-170.	2.4	21
65	Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. <i>Endocrine-Related Cancer</i> , 2017, 24, 243-251.	3.1	45
66	Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1236-1242.	5.0	29
67	Scalp hair cortisol for diagnosis of Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2017, 176, 695-703.	3.7	31
68	Identification of Mutations in Cell-Free Circulating Tumor DNA in Adrenocortical Carcinoma: A Case Series. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3611-3615.	3.6	24
69	Patient-specific workup of adrenal incidentalomas. <i>European Journal of Radiology Open</i> , 2017, 4, 108-114.	1.6	10
70	Severe Cushing's syndrome and bilateral pulmonary nodules: beyond ectopic ACTH. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2017, 2017, .	0.5	2
71	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 569-576.	3.7	75
72	Plasma acylated and plasma unacylated ghrelin: useful new biomarkers in patients with neuroendocrine tumors?. <i>Endocrine Connections</i> , 2016, 5, 143-151.	1.9	4

#	ARTICLE	IF	CITATIONS
73	Coagulation Profile Dynamics in Pediatric Patients with Cushing Syndrome: A Prospective, Observational Comparative Study. <i>Journal of Pediatrics</i> , 2016, 177, 227-231.	1.8	9
74	Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours. <i>European Journal of Endocrinology</i> , 2016, 175, 361-366.	3.7	42
75	Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?. <i>Neuroendocrinology</i> , 2016, 103, 560-566.	2.5	30
76	Prevalence, Clinical Management, and Natural Course of Incidental Findings on Brain MR Images: The Population-based Rotterdam Scan Study. <i>Radiology</i> , 2016, 281, 507-515.	7.3	110
77	Complex MAX Rearrangement in a Family With Malignant Pheochromocytoma, Renal Oncocytoma, and Erythrocytosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 453-460.	3.6	47
78	Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells. <i>Endocrine</i> , 2016, 52, 664-667.	2.3	8
79	Peptide receptor radionuclide therapy of neuroendocrine tumours. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2016, 30, 103-114.	4.7	54
80	Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. <i>European Journal of Endocrinology</i> , 2016, 174, 651-662.	3.7	40
81	Ziekte van Cushing. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2015, 31, 271-277.	0.0	0
82	Cushing's syndrome: epidemiology and developments in disease management. <i>Clinical Epidemiology</i> , 2015, 7, 281.	3.0	166
83	Cushing's syndrome. <i>Lancet, The</i> , 2015, 386, 913-927.	13.7	988
84	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 841-849.	3.6	274
85	Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives. <i>Annales D'Endocrinologie</i> , 2015, 76, 43-58.	1.4	17
86	Cushing's syndrome: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1829-1844.	1.8	25
87	What's new on the HPA axis?. <i>Intensive Care Medicine</i> , 2015, 41, 1477-1479.	8.2	5
88	Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [¹⁷⁷ Lu-DOTA ⁰ , Tyr ³]Octreotate. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1647-1653.	5.0	97
89	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. <i>Endocrine-Related Cancer</i> , 2014, 21, 601-613.	3.1	25
90	Parathyroid Hormone-Related Peptide (PTHrP) Secretion by Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Clinical Features, Diagnosis, Management, and Follow-Up. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3060-3069.	3.6	56

#	ARTICLE	IF	CITATIONS
91	Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. <i>Endocrine-Related Cancer</i> , 2014, 21, 653-661.	3.1	39
92	Inhibin Alpha-Subunit (INHA) Expression in Adrenocortical Cancer Is Linked to Genetic and Epigenetic INHA Promoter Variation. <i>PLoS ONE</i> , 2014, 9, e104944.	2.5	10
93	Recent Developments in Drug Therapy for Cushing's Disease. <i>Drugs</i> , 2013, 73, 907-918.	10.9	3
94	Glucocorticoid sensitivity in health and disease. <i>Nature Reviews Endocrinology</i> , 2013, 9, 670-686.	9.6	253
95	Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3 months: post hoc analyses from the tREACH study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1659-1663.	0.9	16
96	Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2013, 169, 51-58.	3.7	16
97	Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after 177Lu-octreotate. <i>Endocrine-Related Cancer</i> , 2013, 20, 825-831.	3.1	35
98	The prevalence and relevance of adrenal masses in patients with sporadic gastroenteropancreatic neuroendocrine tumours (GEP- $\hat{=}$ NET). <i>Clinical Endocrinology</i> , 2013, 78, 950-956.	2.4	3
99	Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E66-E71.	3.6	129
100	Medical Treatment of Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 425-438.	3.6	125
101	Increased myocardial fibrosis and left ventricular dysfunction in Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2012, 166, 27-34.	3.7	62
102	Pasireotide. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 597-598.	46.4	24
103	Serum inhibin pro- $\hat{=}$ C is a tumor marker for adrenocortical carcinomas. <i>European Journal of Endocrinology</i> , 2012, 166, 281-289.	3.7	11
104	Occurrence of second primary malignancies in patients with neuroendocrine tumors of the digestive tract and pancreas. <i>Endocrine-Related Cancer</i> , 2012, 19, 95-99.	3.1	41
105	Measuring cortisol levels in hair: potential clinical applications in Cushing's syndrome. <i>Expert Review of Endocrinology and Metabolism</i> , 2012, 7, 123-125.	2.4	2
106	Endoscopic bilateral adrenalectomy in patients with ectopic Cushing's syndrome. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 1140-1145.	2.4	17
107	Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. <i>Clinical Endocrinology</i> , 2012, 77, 99-105.	2.4	54
108	New therapeutic options for metastatic malignant insulinomas. <i>Clinical Endocrinology</i> , 2011, 75, 277-284.	2.4	54

#	ARTICLE	IF	CITATIONS
109	Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients. <i>Pituitary</i> , 2011, 14, 253-258.	2.9	32
110	The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. <i>European Journal of Endocrinology</i> , 2011, 165, 383-392.	3.7	322
111	Salvage Therapy with ¹⁷⁷ Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2010, 51, 383-390.	5.0	112
112	Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2010, 162, 331-340.	3.7	87
113	Medical Treatment of Cushing's Syndrome: Adrenal-Blocking Drugs and Ketoconazole. <i>Neuroendocrinology</i> , 2010, 92, 111-115.	2.5	86
114	Pituitary tumours: The sst/D2 receptors as molecular targets. <i>Molecular and Cellular Endocrinology</i> , 2010, 326, 89-98.	3.2	68
115	Coexpression of Dopamine and Somatostatin Receptor Subtypes in Corticotroph Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 1118-1124.	3.6	109
116	Medical Therapy of Acromegaly. <i>Drugs</i> , 2009, 69, 2207-2226.	10.9	73
117	Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease After Eight Years of Dopamine Agonist Therapy for Prolactinoma. <i>Obstetrical and Gynecological Survey</i> , 2009, 64, 107-108.	0.4	0
118	Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. <i>Endocrine-Related Cancer</i> , 2008, 15, 583-596.	3.1	93
119	Treatment With the Radiolabeled Somatostatin Analog [¹⁷⁷ Lu-DOTA ⁰ , Tyr ³]Octreotate: Toxicity, Efficacy, and Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 2124-2130.	1.6	1,307
120	Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3348-3356.	3.6	128
121	Adrenal insufficiency occurring seven years after nephrectomy for renal cell cancer. <i>Acta Oncologica</i> , 2007, 46, 121-122.	1.8	2
122	Long-Term Efficacy and Safety of Combined Treatment of Somatostatin Analogs and Pegvisomant in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4598-4601.	3.6	146
123	Prediction of Mortality Risk in the Elderly. <i>American Journal of Medicine</i> , 2006, 119, 519-525.	1.5	122
124	Somatostatin receptor imaging for neuroendocrine tumors. <i>Pituitary</i> , 2006, 9, 243-248.	2.9	69
125	Potent Inhibitory Effects of Type I Interferons on Human Adrenocortical Carcinoma Cell Growth. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4537-4543.	3.6	40
126	Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epideptide dopamine D2 receptor imaging?. <i>European Journal of Endocrinology</i> , 2006, 155, 717-723.	3.7	20

#	ARTICLE	IF	CITATIONS
127	Effects of therapy with [¹⁷⁷ Lu-DOTA ⁰ , Tyr ³]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1599-606.	5.0	109
128	The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. <i>Clinical Endocrinology</i> , 2005, 63, 176-184.	2.4	59
129	Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. <i>European Journal of Endocrinology</i> , 2005, 153, 67-71.	3.7	42
130	Thyroid Hormone Concentrations, Disease, Physical Function, and Mortality in Elderly Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6403-6409.	3.6	242
131	Expression of the Human Glucocorticoid Receptor Splice Variants $\hat{1}\pm$, $\hat{1}^2$, and P in Peripheral Blood Mononuclear Leukocytes in Healthy Controls and in Patients with Hyper- and Hypocortisolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6237-6243.	3.6	48
132	The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. <i>European Journal of Endocrinology</i> , 2005, 152, 645-654.	3.7	248
133	Radiolabeled Somatostatin Analog [¹⁷⁷ Lu-DOTA ⁰ , Tyr ³]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 2754-2762.	1.6	602
134	Ventilation according to the open lung concept attenuates pulmonary inflammatory response in cardiac surgery†. <i>European Journal of Cardio-thoracic Surgery</i> , 2005, 28, 889-895.	1.4	106
135	Octreotide Exerts Only Acute, but No Sustained, Effects on MRI Enhancement of Liver Metastases in Carcinoid Syndrome. <i>Neuroendocrinology</i> , 2005, 82, 41-48.	2.5	3
136	The Novel Somatostatin Analog SOM230 Is a Potent Inhibitor of Hormone Release by Growth Hormone- and Prolactin-Secreting Pituitary Adenomas <i>in Vitro</i> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1577-1585.	3.6	178
137	A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 638-645.	3.6	138
138	Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. <i>American Journal of Medicine</i> , 2004, 117, 158-162.	1.5	90
139	Luteinizing Hormone (LH)-Responsive Cushing's Syndrome: The Demonstration of LH Receptor Messenger Ribonucleic Acid in Hyperplastic Adrenal Cells, which Respond to Chorionic Gonadotropin and Serotonin Agonists <i>in Vitro</i> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 230-237.	3.6	84